Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Consumption of Chaya on Lipid Concentration and Antioxidant Status of Patients With Dyslipidemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04110392
Recruitment Status : Recruiting
First Posted : October 1, 2019
Last Update Posted : February 11, 2020
Sponsor:
Information provided by (Responsible Party):
Azalia Avila Nava, Hospital Regional de Alta Especialidad de la Península de Yucatán

Brief Summary:
Currently, the changes generated in lifestyle, such as excessive consumption of saturated fats and refined carbohydrates, as well as the decrease in the intake of fiber, fruits, vegetables and antioxidants, as well as physical inactivity, have generated an increase in the prevalence of dyslipidemias. Dyslipidemias are a disorder of blood lipid and lipoprotein concentration, which increases the risk of developing atherosclerosis and cardiovascular diseases. In Mexico, the dyslipidemias are present in one in four Mexicans over 20 years old. However, in Yucatan increases this frequency increases due to one in three people suffer from dyslipidemia. Its prevalence is even higher in overweight subjects, diabetes and high blood pressure. Thus, it is important to search for strategies to reduce dyslipidemias, as well as the complications associated with them. The treatment and prevention of dyslipidemia is through dietary treatment, which may be accompanied by the consumption of foods that generate beneficial health effects due to the presence of bioactive compounds. Chaya (Cnidoscolus chayamansa) is a plant use in popular medicine to treat medicine in the treatment of chronic degenerative diseases. It contained different bioactive compounds such as flavonoids, vitamin C and polyphenols such as quercetin and kaempferol. Compounds that have been assigned various beneficial effects such as decreased triglyceride concentrations, cholesterol, malondialdehyde, C-Reactive protein, oxidized LDL, which are alterations that are present in dyslipidemia. Therefore, the consumption of this food could be an adequate strategy for subjects with dyslipidemia in Yucatan and Mexico due to the anti-inflammatory and antioxidant effects, and could reduce the risk of developing atherosclerosis and cardiovascular diseases.

Condition or disease Intervention/treatment Phase
Dyslipidemias Dietary Supplement: Chaya (Cnidoscolus chayamansa) Not Applicable

Detailed Description:

The protocol will be carried out in the Hospital Regional de Alta Especialidad de la Península de Yucatán (HRAEPY). It is quasi-experimental and it was proposed before and after study, the study will be consisting in 6 subsequent visits and a last visit to deliver results to the participant.

In the pre-visit, the subjects will be evaluated to determine if they meet the inclusion criteria. They will be explained what the study consists of, the characteristics, the risks and the expected benefits after the intervention, they will be asked to read the consent letter, doubts will be clarified about it and if the participant agrees to be in the study the signature will be made of the consent letter.

At the beginning and end will be taken two blood samples of 5 mL to each participant. One will be to obtain the serum and measure cholesterol-HDL, cholesterol-LDL, triglycerides, total cholesterol, glucose, antioxidant activity, malondialdehyde (MDA) and C-reactive protein. The second sample will be to the extraction of peripheral leukocyte blood mononuclear cells and determine the gene expression of antioxidants enzymes superoxide dismutase (SOD) and catalase (CAT). Blood pressure will be measured with a digital baumanometer while the participant will remain seated with the right arm uncovered. The measurement will be carried out 6 times, in intervals of 3 minutes. The first measurement will be discarded and the average of the remaining measurements will be reported. In the visits will bring to each participant an attachment to reported intake of the beverage. During the following ones it will always be questioned if there is any problem with the drinking the beverage of Chaya.

At the end of the study, participants will be given the document with their results and will be given recommendations for weight control, dietary recommendations to improve lipid concentrations. They will refer to their doctor for follow-up with their laboratory results for their control.

Description of the intervention

Chaya Water Beverage of Chaya will be prepared as follows: 40 g of Chaya leaves will be treated with a commercial brand disinfectant following the manufacturer's instructions for use, then added 1L of purified water and mixed in blender. Finally, 500 mL of it will be placed in bottles. Participants will be instructed to consume 1 bottle per day for 6 weeks. 7 bottles will be delivered at each visit, which will be consumed during the week; participants will be instructed to keep the water refrigerated until it is consumed.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: It is quasi-experimental and it was proposed before and after study, the study will be consisting of a pre-visit, 6 subsequent visits and a last visit to deliver results to the participant.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effect of Consumption of a Beverage of Chaya (Cnidoscolus Chayamansa) on Lipid Concentration, Lipid Peroxidation and Antioxidant Status of Patients With Dyslipidemia
Actual Study Start Date : June 1, 2019
Actual Primary Completion Date : September 23, 2019
Estimated Study Completion Date : December 7, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Antioxidants

Arm Intervention/treatment
Experimental: Chaya (Cnidoscolus chayamansa)
Chaya Water Beverage of Chaya will be prepared as follows: 40 g of Chaya leaves will be treated with a commercial brand disinfectant following the manufacturer's instructions for use, then added 1L of purified water and mixed in blender. Finally, 500 mL of it will be placed in bottles. Participants will be instructed to consume 1 bottle per day for 6 weeks. 7 bottles will be delivered at each visit, which will be consumed during the week; participants will be instructed to keep the water refrigerated until it is consumed.
Dietary Supplement: Chaya (Cnidoscolus chayamansa)
Chaya Water Beverage of Chaya will be prepared as follows: 40 g of Chaya leaves will be treated with a commercial brand disinfectant following the manufacturer's instructions for use, then added 1L of purified water and mixed in blender. Finally, 500 mL of it will be placed in bottles. Participants will be instructed to consume 1 bottle per day for 6 weeks. 7 bottles will be delivered at each visit, which will be consumed during the week; participants will be instructed to keep the water refrigerated until it is consumed.




Primary Outcome Measures :
  1. Change from baseline triglycerides concentration at 6 weeks of intervention [ Time Frame: At the beginning of the study and after 6 weeks of intervention ]
    Serum triglyceride measurement by the method of colorimetry enzymatic

  2. Change from baseline Lipoproteins concentration at 6 weeks of intervention [ Time Frame: At the beginning of the study and after 6 weeks of intervention ]
    Total cholesterol, LDL and HDL measurement by the method of colorimetry enzymatic


Secondary Outcome Measures :
  1. Change from baseline blood gene expression of superoxide dismutase at 6 weeks of intervention [ Time Frame: At the beginning of the study and after 6 weeks of intervention ]
    Gene expression of superoxide dismutase measurement by qPCR method

  2. Change from baseline blood gene expression of catalase at 6 weeks of intervention [ Time Frame: At the beginning of the study and after 6 weeks of intervention ]
    Blood gene expression of catalase measurement by quantitative polymerase chain reaction (qPCR) method

  3. Change from baseline serum antioxidant activity at 6 weeks of intervention [ Time Frame: At the beginning of the study and after 6 weeks of intervention ]
    Serum antioxidant activity measurement by spectrophotometric method

  4. Change from baseline serum C-Reactive Protein at 6 weeks of intervention [ Time Frame: At the beginning of the study and after 6 weeks of intervention ]
    Serum C-Reactive Protein measurement by the method of colorimetry enzymatic



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female.
  • Adults between 20 and 60 years.
  • BMI ≥ 20 and ≤ 39.9 kg / m².
  • Mestizo Mexicans: parents and grandparents born in Mexico.
  • Patients diagnosed with dyslipidemia.
  • Dyslipidemia will be defined by any? alteration in the concentrations of the following lipoproteins: LDL cholesterol> 130mg/dL or total cholesterol> 200 mg/dL or triglycerides> 150 mg/dL
  • Patients should know how to read and write.
  • Signature of informed consent.

Exclusion Criteria:

  • Patients with any type of diabetes previously diagnosed
  • Patients with acquired diseases that produce secondary obesity and diabetes.
  • Patients who have suffered a cardiovascular event.
  • Weight loss> 3 kg in the last 3 months.
  • Catabolic diseases such as cancer and acquired immunodeficiency syndrome.
  • Positive smoking.
  • Drug treatment:

    • Antihypertensive drugs (thiacyclic, loop or potassium-sparing diuretics, angiotensin II receptor blockers, alpha blockers, calcium antagonists, beta blockers).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04110392


Contacts
Layout table for location contacts
Contact: Azalia Avila Nava, PhD +52 999 94 27600 ext 54440 azalia.avila@salud.gob.mx

Locations
Layout table for location information
Mexico
Hospital Regional de Alta Especialidad de la Península de Yucatán Recruiting
Mérida, Yucatán, Mexico, 97130
Contact: Azalia Avila Nava, PhD    +52 999 94 27600 ext 54420    azalia.avila@salud.gob.mx   
Contact: PhD         
Sponsors and Collaborators
Hospital Regional de Alta Especialidad de la Península de Yucatán
Publications:
Layout table for additonal information
Responsible Party: Azalia Avila Nava, Researcher in medical sciences, Hospital Regional de Alta Especialidad de la Península de Yucatán
ClinicalTrials.gov Identifier: NCT04110392    
Other Study ID Numbers: 2018-030
First Posted: October 1, 2019    Key Record Dates
Last Update Posted: February 11, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases